Menu Search
Equities

Citius Pharmaceuticals Inc

47N:STU

Citius Pharmaceuticals Inc

Actions
  • Price (EUR)0.1523
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-78.12%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

  • Revenue in USD (TTM)0.00
  • Net income in USD-39.77m
  • Incorporated2010
  • Employees22.00
  • Location
    Citius Pharmaceuticals Inc11 Commerce Dr Fl 1CRANFORD 07016-3501United StatesUSA
  • Phone+1 (908) 967-6677
  • Websitehttps://www.citiuspharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.